Biosimilars
- Critical appraisal and future outlook on anti-inflammatory biosimilar use in chronic immune-mediated inflammatory diseases
- Biosimilars – What IBD Patients Should Know
- Biosimilar Patient and Prescriber Outreach Materials
- Biosimilar Development, Review, and Approval
- Biosimilars Basics infographic for Patients
- What is a Biosimilar?
- Prescribing Biosimilar Products
- Biosimilar Development Process
Cirrhosis
- How Do Patients With Cirrhosis and Their Caregivers Learn About and Manage Their Health? A Review and Qualitative Study
- Cirrhosis
- Hepatic Encephalopathy
Eosinophilic Esophagitis (EoE)
- AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis
- Disease Burden and Unmet Need in Eosinophilic Esophagitis
- Biologics in Eosinophilic Gastrointestinal Diseases
- Pathophysiology of Eosinophilic Esophagitis
- Environmental Factors and Eosinophilic Esophagitis
- International Consensus Diagnostic Criteria for Eosinophilic Esophagitis
- Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis
- Treatment of Eosinophilic Esophagitis: Clinical Decision Support Tool
- Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis in Adolescents and Adults: Results From a Phase 3, Randomized, Placebo-Controlled Trial
Hepatitis C Virus (HCV)
- AGA Hepatitis C Virus FAQs
- AGA GI Patient Center: Hepatitis C (HCV)
- HCV Next
- Direct-Acting Antivirals: Side Effects Management Handouts
- CDC Hepatitis C Resource Center
- Patient-Reported Outcomes for Patients With Chronic Liver Disease
- U.S. Department of Veterans Affairs: Hepatitis C Resources for Healthcare Professionals and Patients
- Direct-Acting Antivirals: Side Effects Management Handouts
- Hepatitis C Guidance 2019 Update: AASLD‐IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Hepatitis B Virus (HBV)
- CDC Patient Education Center: Hepatitis B Virus
- CDC Testing Asian Americans and Pacific Islanders for Hepatitis
- Q&A: HIV links to diminished control of HBV coinfection
- CDC Interpretation of Hepatitis B Serologic Test Results
- CDC Hepatitis B Resource Center
Inflammatory Bowel Disease (IBD)
- Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
- Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?
- AGA IBD Patient Resources
- Resources For Nurses & Advanced Practice Providers: Crohn’s and Colitis Foundation
- Treat-to-Target in Inflammatory Bowel Diseases, What Is the Target and How Do We Treat?
- Patient Perspectives and Expectations in Inflammatory Bowel Disease: A Systematic Review
- Treat-to-Target Approach in Inflammatory Bowel Disease: The Role of Advanced Practice Providers
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
- AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease
- Symptoms & Causes of Ulcerative Colitis – NIH Patient Information
- Ostomy Tips and Tricks
- United Ostomy Associations of America, Inc. Colostomy facts
- Crohn’s & Colitis Foundation. Free educational brochures
- Modulation of sphingosine-1-phosphate in ulcerative colitis
- Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis
- Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
- A Role for Primary Care Pharmacists in the Management of Inflammatory Bowel Disease? Lessons from Chronic Disease: A Systematic Review
- Inflammatory Bowel Disease Pharmacist Adherence Counseling Improves Medication Adherence in Crohn’s Disease and Ulcerative Colitis
- Shared Decision Making in Gastroenterology:Challenges and Opportunities
- Treatment Approaches in IBD: Shared Decision-Making
- Guidance for Restarting Inflammatory Bowel Disease Therapy in Patients Who Withheld Immunosuppressant Medications During COVID-19
- Coronavirus and IBD Reporting Database
- An Overview of Novel and Emerging Therapies for Inflammatory Bowel Disease
- Understanding IBD Medications and Side Effects (Patient Handout)
- Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts
- Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances
- Emotional Well-being Questionnaire – A Patient/Provider Communication Aid
- Which IBD Medication is Right for Me?
- Vedolizumab Prescribing Information
- IBD Checklist for Monitoring & Prevention
- IBD Checklist for Care Continuity
- Ostomates Food Reference Chart
- Ostomy Resources
- ACG Clinical Guideline – Ulcerative colitis in Adults
- The Development of Patient-Reported Outcome Measures in Inflammatory Bowel Disease
- Emerging Therapies for Inflammatory Bowel Disease
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis
- Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
- Emerging therapies for the treatment of ulcerative colitis
- A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review
Lysosomal Acid Lipase Deficiency (LAL-D)
- Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group
- Lysosomal Acid Lipase Deficiency (LALD) – Patient Information
Non-Alcoholic Fatty Liver Disease (NAFLD)
- Screening for Nonalcoholic Fatty Liver Disease in the Primary Care Clinic
- Review of Clinical Guidelines in the Diagnosis of Pediatric Nonalcoholic Fatty Liver Disease
- The diagnosis and management of nonalcoholic fatty liver disease: A patient‐friendly summary of the 2018 AASLD guidelines
- NAFLD: Differential Diagnosis – Summary
- NIH Genetic and Rare Diseases Information Center: Lysosomal acid lipase deficiency
- The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance From the AASLD